There are currently 72 clinical trials in Huntsville, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including Heart Center Research, Llc, Clearview Cancer Institute, Medical Affiliated Research Center, Inc and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Pivotal Study for the Cardiac Performance System (CPS)
NCT06870591
Recruiting
This multi-center, observational study evaluates the accuracy of the Cardiac Performance System (CPS), a non-invasive device, for measuring hemodynamic parameters in adult patients undergoing clinically indicated right heart catheterization. The study compares CPS measurements to invasive measurements to assess agreement and potential clinical utility.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Huntsville Hospital Heart Center, Huntsville, Alabama
Conditions: Cardiovascular Diseases
Register for Updates
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
NCT04955795
Recruiting
This study is designed to examine the efficacy of a brief intervention plus a cognitive-behavioral intervention compared to brief intervention alone to address unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among people living with HIV in Alabama.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/01/2025
Locations: Thrive, Huntsville, Alabama
Conditions: Hiv, Alcohol Problem
Register for Updates
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Heart Center Rsrch_Hunstville, Huntsville, Alabama
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/25/2025
Locations: Heart Center LLC, Huntsville, Huntsville, Alabama
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/22/2025
Locations: Research Site, Huntsville, Alabama
Conditions: Acute Coronary Syndrome
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Triple Negative Breast Cancer
Register for Updates
In-Office Clinical Study of the Solo+ TTD
NCT05741333
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the Solo+ Tympanostomy Tube Device (Solo+ TTD) for the placement of tympanostomy tubes in paediatric patients undergoing a tympanostomy procedure.
Gender:
ALL
Ages:
Between 6 months and 13 years
Trial Updated:
04/15/2025
Locations: North Alabama ENT, Huntsville, Alabama
Conditions: Ear Infection, Otitis Media
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Huntsville, Alabama
Conditions: Generalized Anxiety Disorder
Register for Updates
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT06919328
Recruiting
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
04/07/2025
Locations: Nutraceuticals Research Institute, Huntsville, Alabama
Conditions: Healthy Aging
Register for Updates
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
NCT06092970
Recruiting
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: * Patient reported outcomes (PRO), using the EQ-5D questionnaire * Clinical outcomes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Research Site, Huntsville, Alabama
Conditions: Post-Operative Complications in Cardiac Surgery
Register for Updates
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: North Alabama GI Research Center, Huntsville, Alabama
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
The Effectiveness of a Proprietary of a Botanical Extract on Sleep Quality
NCT06894108
Recruiting
The purpose of this study is to evaluate the efficacy and superiority of a botanical based sleep product on sleep quality as compared to melatonin, among healthy female participants.
Gender:
FEMALE
Ages:
Between 35 years and 55 years
Trial Updated:
03/19/2025
Locations: Nutraceuticals Research Institute, Huntsville, Alabama
Conditions: Sleep
Register for Updates